About the Event
Back pain is the number one cause of disability around the world. Epidural steroid injections can offer some relief, but often need to be delivered far too frequently, with patients visiting their physicians every 30 days or less in pursuit of a pain-free back. SpineThera has developed a sustained release, microsphere delivery platform that outpaces all currently available epidural injectable steroids on two fronts:
- Clinical trials show SpineThera microsphere technology provides relief for 60 to 90 days with 71% of respondents reporting a 50% or greater reduction in pain after 60 days.
- Because the microspheres are so small (1/2 the size of a red blood cell), SpineThera’s formulation can contain 50 times higher drug concentrations, meaning treatments can be precision targeted.
SpineThera has completed a Phase 1/2 clinical trial in Australia with the unprecedented results mentioned above. They are in talks with the FDA to move forward with trials in the US.
Long term, this is a platform technology with multiple high value applications beyond back pain. SpineThera’s has a robust patent portfolio protecting the microsphere delivery system.